We previously reported that a nonpeptidic OX2R-selective agonist, YNT-185, promotes wakefulness and ameliorates cataplexy-like episodes in mouse models of narcolepsy such as orexin knockout and orexin neuron-ablated mice [19]. This evidence concerns the gene HCRT and narcolepsy.